APA (7th ed.) Citation

DF, M., JA, S., M, S., C, M., MS, G., O, H., . . . T, P. (2016). Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34(8), 833. https://doi.org/10.1200/JCO.2015.63.7421

Chicago Style (17th ed.) Citation

DF, McDermott, et al. "Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 34, no. 8 (2016): 833. https://doi.org/10.1200/JCO.2015.63.7421.

MLA (9th ed.) Citation

DF, McDermott, et al. "Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 34, no. 8, 2016, p. 833, https://doi.org/10.1200/JCO.2015.63.7421.